NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 206 filers reported holding NEVRO CORP in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $15,000 | -11.8% | 331 | +38.5% | 0.00% | – |
| Q1 2022 | $17,000 | -15.0% | 239 | -4.0% | 0.00% | – |
| Q4 2021 | $20,000 | +33.3% | 249 | +88.6% | 0.00% | – |
| Q3 2021 | $15,000 | -58.3% | 132 | -39.4% | 0.00% | – |
| Q2 2021 | $36,000 | +176.9% | 218 | +139.6% | 0.00% | – |
| Q1 2021 | $13,000 | -56.7% | 91 | -46.8% | 0.00% | – |
| Q4 2020 | $30,000 | +25.0% | 171 | -1.7% | 0.00% | – |
| Q3 2020 | $24,000 | +20.0% | 174 | +3.0% | 0.00% | – |
| Q2 2020 | $20,000 | +400.0% | 169 | +267.4% | 0.00% | – |
| Q3 2019 | $4,000 | -20.0% | 46 | -37.0% | 0.00% | – |
| Q2 2019 | $5,000 | 0.0% | 73 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | 0.0% | 73 | -37.6% | 0.00% | – |
| Q4 2018 | $5,000 | -28.6% | 117 | 0.0% | 0.00% | – |
| Q3 2018 | $7,000 | -22.2% | 117 | 0.0% | 0.00% | – |
| Q2 2018 | $9,000 | +800.0% | 117 | +1571.4% | 0.00% | – |
| Q1 2018 | $1,000 | – | 7 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |